Emily Cridland

Emily’s representative transactions include advising:

• Bain & Company on its acquisition of JJCFinTech, a London-based boutique financial services consulting and technology firm
• Anglo American on the:
  • Sale of its Australian steelmaking coal business to Peabody Energy Corporation for US$3.775 billion
  • Sale of its 33.3% minority interest in Jellinbah Group Pty Ltd to Zashvin Pty Limited for A$1.6 billion
  • US$3.8 billion disposal of its steelmaking coal business in Australia to Dhilmar Limited, a UK-based private mining company
• Novo Holdings on its agreement to acquire the Norwegian fish genetics company Benchmark Genetics from Benchmark Holdings plc for an enterprise value of up to £260 million
• Ericsson on its joint venture with some of the world’s largest telecom operators — including América Móvil, AT&T, Bharti Airtel, Deutsche Telekom, Orange, Reliance Jio, Singtel, Telefonica, Telstra, T-Mobile, Verizon, and Vodafone — to combine and sell network Application Programming Interfaces (APIs) on a global scale to spur innovation in digital services
• Cadence Design Systems in its acquisition of BETA CAE for US$1.24 billion
• atai Life Sciences on its investment into Beckley Psytech Limited, a clinical-stage biotechnology company focused on developing novel psychedelic therapies
• System1, Inc. on the sale of Total Security Limited, a cybersecurity company, to a group led by Just Develop It Limited
• Ericsson / Cradlepoint on its acquisition of cloud-based security specialist Ericom
• IHS Markit on its joint venture with PIMCO, Man Property Holdings, State Street, and Microsoft to set up a new technology-led company, HUB, to build a cloud-based operating platform aimed at transforming asset managers’ operations technology
• Novo Holdings A/S on its acquisition of BBI Group, a leading supplier of products and services to the global diagnostics and life sciences industries
• Nordic Capital on its acquisition of ADVANZ PHARMA, a London-based pharmaceutical company
• Ligand Pharmaceuticals on its sale of Vernalis (R&D) Limited, a UK-based fragment and structure-based drug discovery research company, to HitGen
• Eleusis Holdings on its acquisition of Kalypso Treatment Centers, a leading provider of ketamine infusion therapies in the United States
• Nestlé Health Science on its acquisition of Vital Proteins
• Atnahs Pharma on its acquisition of assets related to five hypertension medicine brands from AstraZeneca
• Thomas Cook Group in connection with its strategic review, re-financing and the proposed sale of its airline and ultimately its attempted recapitalization
• Sony Pictures Entertainment and its subsidiary, Columbia Pictures Corporation, on the acquisition of Silvergate Media, a developer of children’s brands for broadcasters, streaming platforms, and retail partners (including the Octonauts, Peter Rabbit, and Hilda animated series)
• GlaxoSmithKline on its:
  • Divestment of its Prevacid®24HR business to Perrigo Company
  • Divestment of assets relating to the Bialcol and Cibalgina brands in Italy to Vemedia
  • Divestment of certain North American consumer health assets to Crown Laboratories
  • Divestment of five over-the-counter dermatology brands and one pediatric cough remedy brand to the STADA Group
• Peloton Advantage, a portfolio company of Amulet Capital Partners, on the acquisition of Open Health Communications, a UK-based provider of healthcare communications and market access services
• Netflix on the acquisition of Millarworld, the comic book company founded by Mark Millar, creator of a number of iconic characters and stories, including Kick-Ass, Kingsman, and Old Man Logan, the first ever acquisition by Netflix
• ACCO Brands Corporation in connection with its €296.9 million acquisition of Esselte Group, a leading European office products company, from private equity firm J.W. Childs
• Astorg Partners on its acquisition of Audiotonix, a global producer of audio mixing consoles